<DOC>
	<DOCNO>NCT01856764</DOCNO>
	<brief_summary>The purpose study evaluate effect topical roflumilast reduction atopic dermatitis lesion adult atopic dermatitis .</brief_summary>
	<brief_title>Topical Roflumilast Adults With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Phosphodiesterase 4 Inhibitors</mesh_term>
	<criteria>1 . Is male female 18 65 year age , inclusive , atopic dermatitis ( AD ) meeting Hanifin Rajka 's criterion . 2 . Has lesional skin area moderate severity characterize modify local SCORing Atopic Dermatitis ( SCORAD ) least 4 , erythema score ≥2 , confirm qualified investigator . 3 . Has index/target lesion moderate severity approximately 20 cm^2 , suitable topical treatment . 4 . Is willing wash AD current active therapy prior entry study . 5 . Is willing able apply study medication direct , comply study instruction commit followup visit duration study . 6 . If male nonsterilized sexually active female partner childbearing potential , agree use adequate contraception signing inform consent throughout duration study 12 week last dose . 7 . If female childbearing potential sexually active nonsterilized male partner , agree use routinely adequate contraception signing inform consent throughout duration study 12 week last dose . 8 . Is capable understand comply protocol requirement opinion investigator . 9 . Signs date write informed consent form require privacy authorization prior initiation study procedure . 1 . Has receive investigational compound within 30 day , within 5 halflives compound ( whichever longer ) prior Screening visit . 2 . Has history AD unresponsive poorly responsive topical treatment . 3 . Has history hypersensitivity phosphodiesterase ( PDE ) 4 inhibitor drug similar chemical class inactive ingredient trial medication . 4 . Has clinically significant abnormal hematological parameter hemoglobin , hematocrit erythrocyte Screening , judgment investigator . 5 . Has history current clinically relevant allergy idiosyncrasy drug food . 6 . Had extensive exposure ultraviolet ( UV ) light 4 week prior first application study medication , include tan sun bed intend exposure study treatment may interfere study assessment judge investigator . 7 . Has evidence ooze target lesion . 8 . Has current skin complication erythroderma overt bacterial viral infection treatment antiinfectives indicate . 9 . Had systemic treatment corticosteroid retinoids study condition within 3 month prior first application study medication . 10 . Had topical transdermal treatment , limited retinoids , nicotine hormone replacement therapy , near intend site application within 4 week prior first application study medication . 11 . Had treatment systemic/locally act medications/procedures might counter influence study aim within 4 week prior first application study medication study ( e.g. , antihistamine ) . 12 . Has use emollients/moisturizers area treat within 24 hour prior first application study medication . 13 . Has use biologics time treatment AD . 14 . Is currently enrol investigational drug device study . 15 . Has clinically significant illness may influence outcome trial 4 week Day 1 trial completion . 16 . Has alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) value great 2.0 × upper limit normal ( ULN ) , clinically significant abnormal laboratory test , opinion Investigator , would compromise participant 's ability safely complete trial . 17 . Has significant medical condition and/or condition , opinion Investigator , would interfere treatment , safety compliance protocol . 18 . Has history infection hepatitis B , hepatitis C , human immunodeficiency virus . 19 . Has history alcoholism illicit drug abuse within 5 year prior Screening Visit currently consume &gt; 14 alcoholic drink per week . 20 . If female , pregnant , nurse plan pregnancy study period . 21 . Has history cancer remission least 5 year prior first dose study medication . This criterion apply participant successfully resect basal cell stage I squamous cell carcinoma skin . 22 . Has chronic clinically relevant acute infection . 23 . Has history depression associate suicidal ideation behavior . 24 . Has hemodynamically significant cardiac arrhythmias heart valve deformation . 25 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) risk consent duress . 26 . Was institutionalized legal regulatory order .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Atopic dermatitis</keyword>
</DOC>